Literature DB >> 22246387

Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab.

Tatsuya Yunoki1, Akio Miyakoshi, Tomoko Nakamura, Kazuya Fujita, Chiharu Fuchizawa, Atsushi Hayashi.   

Abstract

PURPOSE: We examined the predictive factors for final visual acuity (VA) with macular edema of branch retinal vein occlusion (BRVO) treated by intravitreal injection of bevacizumab (IVB) and examined the differences between patients without recurrent macular edema due to BRVO after a single IVB and patients treated with multiple IVB because of recurrent macular edema.
METHODS: In this retrospective study, 37 eyes of 37 patients with BRVO were treated with IVB and followed up for more than 24 weeks. Eighteen eyes showed no recurrence of macular edema after a single IVB (single IVB group). The remaining 19 eyes showed recurrent macular edema and underwent multiple IVB (multiple IVB group). VA and morphologic parameters of optical coherence tomography were examined.
RESULTS: Mean VA, central retinal thickness, and mean retinal thickness in a circular region of 1-mm diameter at the fovea improved significantly with IVB treatment in both groups. Final VA was correlated with baseline VA and integrity grade of the photoreceptor inner and outer segment (IS/OS) line beneath the fovea.
CONCLUSION: Baseline VA and IS/OS line grade at 4 weeks may be predictive factors for final VA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246387     DOI: 10.1007/s10384-011-0114-3

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  15 in total

1.  Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.

Authors:  Mineo Kondo; Nagako Kondo; Yasuki Ito; Shu Kachi; Masato Kikuchi; Tetsuhiro R Yasuma; Ichiro Ota; Miyake Kensaku; Hiroko Terasaki
Journal:  Retina       Date:  2009-10       Impact factor: 4.256

2.  OCT patterns of macular edema and response to bevacizumab therapy in retinal vein occlusion.

Authors:  Alexandra Eva Hoeh; Mira Ruppenstein; Thomas Ach; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-07-02       Impact factor: 3.117

3.  Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6.

Authors:  Hidetaka Noma; Hideharu Funatsu; Makiko Yamasaki; Hidetoshi Tsukamoto; Tatsuya Mimura; Takashi Sone; Koji Jian; Ikuo Sakamoto; Kensuke Nakano; Hidetoshi Yamashita; Atsushi Minamoto; Hiromu K Mishima
Journal:  Am J Ophthalmol       Date:  2005-08       Impact factor: 5.258

4.  Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.

Authors:  Thomas Ach; Alexandra E Hoeh; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-09       Impact factor: 3.117

5.  Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.

Authors:  T C Kreutzer; C S Alge; A H Wolf; D Kook; J Burger; R Strauss; C Kunze; C Haritoglou; A Kampik; S Priglinger
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

6.  Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion.

Authors:  Atsushi Sakamoto; Akitaka Tsujikawa; Masafumi Ota; Noritatsu Yamaike; Yuriko Kotera; Kazuaki Miyamoto; Mihori Kita; Nagahisa Yoshimura
Journal:  Clin Exp Ophthalmol       Date:  2009-03       Impact factor: 4.207

7.  Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion.

Authors:  Eun Jee Chung; Young Taek Hong; Sung Chul Lee; Oh Woong Kwon; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-11       Impact factor: 3.117

8.  Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.

Authors:  Melvin D Rabena; Dante J Pieramici; Alessandro A Castellarin; Ma'an A Nasir; Robert L Avery
Journal:  Retina       Date:  2007 Apr-May       Impact factor: 4.256

9.  Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.

Authors:  Katharina Kriechbaum; Franz Prager; Wolfgang Geitzenauer; Thomas Benesch; Christopher Schütze; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2009-09-10       Impact factor: 12.079

10.  Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion.

Authors:  Maurizio Battaglia Parodi; Giuseppe DI Stefano; Giuseppe Ravalico
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

View more
  10 in total

1.  Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.

Authors:  Mirae Kim; Seongyong Jeong; Min Sagong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-10-29       Impact factor: 3.117

2.  Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion.

Authors:  Ryo Terao; Kentaro Yuda; Kayo Kure; Tatsuya Inoue; Hiroshi Ohtsu; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2014-01-10       Impact factor: 2.447

Review 3.  Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion.

Authors:  Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2018-03-23       Impact factor: 2.447

4.  Branch retinal vein occlusion-associated subretinal hemorrhage.

Authors:  Yuki Muraoka; Akitaka Tsujikawa; Tomoaki Murakami; Ken Ogino; Kazuaki Miyamoto; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

5.  Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study.

Authors:  Young Hee Yoon; Ha Kyoung Kim; Hee Seong Yoon; Se Woong Kang; June-Gone Kim; Kyu Hyung Park; Young Joon Jo; Joo Yong Lee; Dong Hoon Lee
Journal:  Jpn J Ophthalmol       Date:  2014-01-31       Impact factor: 2.447

6.  Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion.

Authors:  Yuka Ito; Yoshitsugu Saishin; Osamu Sawada; Masashi Kakinoki; Taichiro Miyake; Tomoko Sawada; Hajime Kawamura; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2015-01-23

7.  Natural Short-term Course of Recurrent Macular Edema Following Intravitreal Bevacizumab Therapy in Branch Retinal Vein Occlusion.

Authors:  Su Jin Yoo; Jae Hui Kim; Tae Gon Lee; Jong Woo Kim; Sung Won Cho; Jung Il Han
Journal:  Korean J Ophthalmol       Date:  2017-03-21

Review 8.  The eye and the heart.

Authors:  Josef Flammer; Katarzyna Konieczka; Rosa M Bruno; Agostino Virdis; Andreas J Flammer; Stefano Taddei
Journal:  Eur Heart J       Date:  2013-02-10       Impact factor: 29.983

9.  Effects of Vitrectomy on Recurrent Macular Edema due to Branch Retinal Vein Occlusion after Intravitreal Injection of Bevacizumab.

Authors:  Tatsuya Yunoki; Keiichi Mitarai; Shuichiro Yanagisawa; Tsuyoshi Kato; Nobuo Ishida; Atsushi Hayashi
Journal:  J Ophthalmol       Date:  2013-02-20       Impact factor: 1.909

10.  Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.

Authors:  Vivek B Wani; Jamal Al-Kandari; Khalid Sabti; Faisal Aljassar; Hussain Qali; Niranjan Kumar; Anilkumar Uboweja; Khalid Al-Sabah; Fahad A Diab; Saleh Al-Rashidi
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.